Subsequently, primary cells of 15 MDS/AML patients, whose clinical and cytogenetic features are illustrated in Table 3, were used to evaluate the effect of DFX on the expression of the CDKN1A and PUMA genes. Here, CDKN1A is linked to acute myeloid leukemia.